Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2015.11.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers After Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Cancer Discovery
Oncology
2013English

Therapeutic Targets: MTOR and Related Pathways

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2006English

Impact of Molecular Subtype Conversion of Breast Cancers After Neoadjuvant Chemotherapy on Clinical Outcome

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Molecular Pathways and Therapeutic Targets in Lung Cancer

Oncotarget
Oncology
2014English

Differences Between Invasive Lobular and Invasive Ductal Carcinoma of the Breast: Results and Therapeutic Implications

Therapeutic Advances in Medical Oncology
Oncology
2016English

Clinical Benefit From Neoadjuvant Chemotherapy in Oestrogen Receptor-Positive Invasive Ductal and Lobular Carcinomas

British Journal of Cancer
Cancer ResearchOncology
2013English

Clinical Significance and Prognostic Value of Receptor Conversion in Hormone Receptor Positive Breast Cancers After Neoadjuvant Chemotherapy

World Journal of Surgical Oncology
SurgeryOncology
2018English

Elucidating Therapeutic Molecular Targets in Premenopausal Asian Women With Recurrent Breast Cancers

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

STAT3 and STAT5A Are Potential Therapeutic Targets in Castration-Resistant Prostate Cancer

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy